Hikma Pharmaceuticals (OTCMKTS:HKMPF) Sees Unusually-High Trading Volume – Should You Buy?
by Sarita Garza · The Markets DailyHikma Pharmaceuticals Plc (OTCMKTS:HKMPF – Get Free Report) saw unusually-strong trading volume on Wednesday . Approximately 500 shares changed hands during trading, an increase of 41% from the previous session’s volume of 354 shares.The stock last traded at $20.4903 and had previously closed at $20.94.
Analyst Ratings Changes
Separately, Barclays lowered Hikma Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 6th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.
Get Our Latest Stock Report on HKMPF
Hikma Pharmaceuticals Price Performance
The company has a debt-to-equity ratio of 0.33, a current ratio of 1.24 and a quick ratio of 0.72. The firm has a 50-day moving average price of $20.66 and a 200-day moving average price of $23.13.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.
Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.